Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about GNE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Gene Symbol | GNE |
| Full Name | UDP-N-Acetylglucosamine 2-Epimerase |
| Aliases | Page for GNE |
| Chromosome | 9p13.3 |
| Protein Type | Enzyme |
| Function | GNE encodes a bifunctional enzyme with two catalytic activities |
| UniProt ID | [Q9Y5R9](https://www.uniprot.org/uniprot/Q9Y5R9) |
| Ensembl ID | ENSG00000154217 |
| OMIM | 605828 |
| GeneCards | GNE |
| Human Protein Atlas | GNE |
| Associated Diseases | Als |
| KG Connections | 2 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
GNE["GNE"]
Tumor["Tumor"]
Als["Als"]
neurodegeneration["neurodegeneration"]
GNE -->|"therapeutic target"| Tumor
GNE -->|"associated with"| Als
GNE -->|"implicated in"| neurodegeneration
style GNE fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#fff
style Tumor fill:#3e1a1a,stroke:#ef5350,stroke-width:2px,color:#fff
style Als fill:#3e1a1a,stroke:#ef5350,stroke-width:2px,color:#fff
style neurodegeneration fill:#1a1a2e,stroke:#888,stroke-width:2px,color:#fff| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Magnetosonic-Triggered Transferrin Receptor Clustering | 0.719 | neurodegeneration | Blood-brain barrier transport mechanisms |
| Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m | 0.621 | neurodegeneration | Mitochondrial transfer between astrocyte |
| Synthetic Biology Approach: Designer Mitochondrial Export Sy | 0.505 | neurodegeneration | Mitochondrial transfer between neurons a |
| Magnetic Field Sensing-Memory Interface Therapy | 0.455 | memory-and-navigation | How does ADCY8 mechanistically regulate |
| Magnetic Field Stimulation for Memory Consolidation | 0.455 | spatial-memory | What neural circuits encode and maintain |
| Transcranial Magnetic Stimulation-Induced Nanoparticle Deliv | 0.380 | neurodegeneration | Blood-brain barrier antibody transport m |
| Magnetofection-Enhanced IGFBPL1 Delivery via Superparamagnet | 0.341 | drug-delivery | Can IGFBPL1 therapeutics effectively cro |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| iPSC-derived endothelial cell iron uptake with RLS CSF exposure | exploratory | restless legs syndrome | 0.900 | 0.00 | iPSC-derived human endothelial | proposed | N/A |
| s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $200,000 |
| s:** - Compare uptake with/without magnetic particles using tight junc | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $120,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| s:** - Test MCU overexpression specifically in layer II neurons in hea | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $200,000 |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| AAV-LRRK2 IND-Enabling Study Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Axonal Transport Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Gap Junction Dysfunction Validation in Parkinson's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| AAV-LRRK2 Gene Therapy IND-Enabling Study Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson' | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Selective Neuronal Vulnerability to Aging — Mapping Why Specific Neuro | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease. [PMID:40425446] | Sehlin D, Hultqvist G, Michno W, Aguilar | J Prev Alzheimers Dis | 2025 | 1 |
| Effect of ferroptosis on chronic cerebral hypoperfusion in vascular dementia. [PMID:37709116] | Fu P, Chen Y, Wu M, Bao B, Yin X, Chen Z | Exp Neurol | 2023 | 1 |
| On Iron Metabolism and Its Regulation. [PMID:33925597] | Vogt AS, Arsiwala T, Mohsen M, Vogel M, | Int J Mol Sci | 2021 | 1 |
| Transferrin Receptor Is a Specific Ferroptosis Marker. [PMID:32160546] | Feng H, Schorpp K, Jin J, Yozwiak CE, Ho | Cell Rep | 2020 | 1 |
| Transferrin and transferrin receptors update. [PMID:29969719] | Kawabata H | Free Radic Biol Med | 2019 | 1 |
| KIF5A de novo mutation associated with myoclonic seizures and neonatal onset pro [PMID:27414745] | Rydzanicz M, Jagła M, Kosinska J, Tomasi | Clin Genet | 2017 | 1 |
| TRAK/Milton motor-adaptor proteins steer mitochondrial trafficking to axons and [PMID:23395375] | van Spronsen M, Mikhaylova M, Lipka J, S | Neuron | 2013 | 1 |
| Delineation of the TRAK binding regions of the kinesin-1 motor proteins. [PMID:24161670] | Randall TS, Moores C, Stephenson FA | FEBS Lett | 2013 | 1 |
| Integrating biocatalysis with continuous flow: current status, challenges, and f [PMID:40639553] | Bai J, Huang C, Liu Y, Zheng X, Liu J et | J Adv Res | 2026 | 0 |
| Engineering chimeric signaling proteins for microbial whole-cell biosensors: fro [PMID:40903364] | Özer Bergman G, Mecacci S, Martins Dos S | Trends Biotechnol | 2026 | 0 |
| MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario. [PMID:41512197] | Rodon J, Johnson ML, George B, Shah PA, | Cancer Res | 2026 | 0 |
| Time- and dose-dependent effects of bacterial infection on iron metabolism, infl [PMID:41619877] | Lu Y, Zhang Y, Niu C | Comp Biochem Physiol A Mol Int | 2026 | 0 |
| Ayanin combats against barium sulphate nanoparticles induced hepatotoxicity via [PMID:41666660] | Zhu D, Lu Y, Jamil S, Ashfaq H, Al-Emam | J Trace Elem Med Biol | 2026 | 0 |
| Design and synthesis of BAP-1 inhibitors. [PMID:41761813] | Zhang Z, Yang X | Pak J Pharm Sci | 2026 | 0 |
| Role of iron and TfR1 in the application of high‑dose ascorbate against pancreat [PMID:41789665] | Piotrowsky A, Leischner C, Schmieder H, | Oncol Rep | 2026 | 0 |
| Optimized bacterial expression of a synthetic BRIL antibody. [PMID:41842660] | Cooper BF, Isom GL | Acta Crystallogr F Struct Biol | 2026 | 0 |
| Yangxin granules exert cardioprotective effects against acute myocardial infarct [PMID:41868900] | Huo G, Zhou Y, Wu Z, Sun S, Zhu G, Cheng | American journal of translatio | 2026 | 0 |
| Conformational dynamics study of TfR1 upon transferrin binding via NMA and MD si [PMID:41921418] | Zemmouche M, Falque G, Cadet F, Gardebie | Journal of molecular graphics | 2026 | 0 |
| [Effects of acupuncture on ferroptosis and ferritinophagy in cerebral ischemia-r [PMID:41839581] | Wang YF, Dong YS | Zhen ci yan jiu = Acupuncture | 2026 | 0 |
| The therapeutic potential of Piezo1 channel-mediated ferroptosis and its inhibit [PMID:41854751] | Nan K, Zhang L, Zhao Y, Yin S, Peng Y, H | Apoptosis : an international j | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning GNE in their description or question text
Score: 0.380 · neurodegeneration · 2026-04-26
Transcranial magnetic stimulation (TMS) represents an alternative non-invasive approach for therapeutic delivery to the
Score: 0.341 · drug-delivery · 2026-04-26
The molecular foundation of magnetofection-mediated IGFBPL1 delivery exploits superparamagnetic iron oxide nanoparticles